FORM OF INDEMNIFICATION AGREEMENTIndemnification Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into as of , 201 between Editas Medicine, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
12,500,000 Shares EDITAS MEDICINE, INC. COMMON STOCK, $0.0001 PAR VALUE PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • June 15th, 2023 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • New York
ContractWarrant Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
EDITAS MEDICINE, INC. Nonstatutory Stock Option Agreement Granted Under 2013 Stock Incentive Plan (Early Exercise)Nonstatutory Stock Option Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances)
EDITAS MEDICINE, INC. Incentive Stock Option Agreement Granted Under 2013 Stock Incentive PlanIncentive Stock Option Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances)
COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • March 12th, 2018 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • New York
Editas Medicine, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
EDITAS MEDICINE, INC. Restricted Stock Agreement Granted Under 2013 Stock Incentive PlanRestricted Stock Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
EDITAS MEDICINE, INC. INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances)
This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
EDITAS MEDICINE, INC. NONSTATUTORY STOCK OPTION AGREEMENTNonstatutory Stock Option Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances)
This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. COLLABORATION AND...Collaboration and License Agreement • November 9th, 2021 • Editas Medicine, Inc. • Biological products, (no disgnostic substances)
This COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), effective as of May 26, 2015 (the “Effective Date”), is made by and between Editas Medicine, Inc., a Delaware corporation, having a principal place of business at 300 Third Street, First Floor, Cambridge, MA 02142 (“Editas”), and Juno Therapeutics, Inc., a Delaware corporation, having a place of business at 307 Westlake Avenue North, Suite 300, Seattle, WA 98109 (“Juno”).
June 12, 2014Employment Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
On behalf of Editas Medicine, Inc. (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter agreement (the Agreement”) is to set forth the terms of your employment with the Company, should you accept our offer.
Real Estate License AgreementReal Estate License Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS SUBLEASE AGREEMENT (this “Sublease”) is entered as of the Effective Date by and between Sublandlord and Subtenant on the basis of the following facts, understandings and intentions:
Editas Medicine, Inc. Inducement Stock Option AgreementInducement Stock Option Agreement • February 28th, 2024 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT by and between EDITAS MEDICINE, INC. AND JUNO THERAPEUTICS, INC. May 3, 2018Collaboration and License Agreement • August 7th, 2018 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • New York
This AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), effective as of May 3, 2018 (the “Amendment Date”), is made by and between Editas Medicine, Inc., a Delaware corporation, having a principal place of business at 11 Hurley St, Cambridge, MA 02141 (“Editas”), and Juno Therapeutics, Inc., a Delaware corporation, having a place of business at 400 Dexter Avenue North, Suite 1200, Seattle, WA 98109 (“Juno”) and amends and restates that certain Collaboration and License Agreement by and between Editas and Juno (the “Original Agreement”) dated as of May 26, 2015 (the “Original Agreement Effective Date”).
Sponsored Research AgreementSponsored Research Agreement • October 23rd, 2018 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Sponsored Research Agreement (this “Agreement”), dated as of June 7, 2018 (the “Effective Date”), is made by and between the Broad Institute, Inc. (“Broad”), a non-profit Massachusetts corporation, with a principal office at 415 Main Street, Cambridge, MA 02142, and Editas Medicine, Inc. (“Company”), a Delaware corporation, with a principal office at 11 Hurley Street, Cambridge, Massachusetts 02141. Each of Broad and Company may be referred to herein as a “Party” or together as the “Parties.”
CONSENT TO SUBLEASEConsent to Sublease • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
Editas Medicine, Inc. COMMON STOCK SALES AGREEMENTSales Agreement • February 28th, 2024 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • New York
Editas Medicine, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • California
This LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into as of the date set forth above (the “Effective Date”) by and between SILICON VALLEY BANK (“Bank”), and the borrower named above (“Borrower”). Capitalized terms used but not otherwise defined herein shall have the meanings given them on Schedule C, The parties agree as follows:
SUBLEASESublease • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • May 15th, 2020 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • New York
Editas Medicine, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
THE GENERAL HOSPITAL CORPORATION EXCLUSIVE PATENT LICENSE AGREEMENT MGH Agreement No: A221317 MGH Case Nos: [**]Exclusive Patent License Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This License Agreement (“Agreement”) is made as of the 29th day of August, 2014 (“Effective Date”), by and between Editas Medicine, Inc., a Delaware corporation, with its principal place of business located at 300 Third Street, Cambridge, MA 02142 (“Company”), and The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit Massachusetts corporation, with a principal place of business at 55 Fruit Street, Boston, Massachusetts 02114 (“Hospital”), each referred to herein individually as a “Party” and collectively as the “Parties.”
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions.Exclusive License Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances)
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AGREEMENTLicense Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS Agreement is entered into this 10th day of October, 2014 (“Effective Date”) between DUKE UNIVERSITY, a nonprofit educational and research institution organized under the laws of North Carolina (“DUKE”), having a place of business at Durham, North Carolina 27710, and Editas Medicine, Inc., a corporation organized under the laws of the State of Delaware (“Licensee”), having its principal office at 300 Third Street, First Floor, Cambridge, MA 02142. Duke or Licensee may be referred to herein individually as a “Party” and collectively as the “Parties”.
June 8, 2015 Andrew A. F. Hack, M.D., Ph.D. Apt. 3AB New York, NY 10025 Dear Andrew:Employment Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
On behalf of Editas Medicine, Inc. (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter agreement (the “Agreement”) is to set forth the terms of your employment with the Company, should you accept our offer.
April 8, 2015 Sandra GlucksmannOffer of Employment • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This letter amends and restates the employment letter dated September 19, 2013 between you and Editas Medicine, Inc. (the “Company”) (the “Prior Agreement”). Effective upon the date of this Agreement (the “Effective Date”), your continued employment with the Company shall be on the terms set forth in this Agreement and the Prior Agreement shall be terminated and of no further force or effect.
EDITAS MEDICINE, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT August 4, 2015Investors’ Rights Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 4th day of August, 2015, by and among Editas Medicine, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions.Letter Agreement • February 26th, 2020 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This letter agreement (“Letter Agreement”) is entered into as of the date provided above (the “Effective Date”) by and between, on the one hand, the President and Fellows of Harvard College, an educational and charitable corporation existing under the laws and the constitution of the Commonwealth of Massachusetts, having a place of business at Smith Campus Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, MA 02138 (“Harvard”) and The Broad Institute, Inc., a non-profit Massachusetts corporation, with a principal office at 415 Main Street, Cambridge, MA 02142 (“Broad,” together with Harvard, the “Institutions” and each individually, an “Institution”) and, on the other hand, Editas Medicine, Inc., a Delaware corporation, with a principal office at 11 Hurley Street, Cambridge, MA 02141 (“Company”). Company and the Institutions are each referred to herein as a “Party” and together, the “Parties.”
11 Hurley Street Cambridge, MA 02141 617-401-9000 617-494-0985Employment Offer Letter • August 3rd, 2022 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
Reference is made to that certain Employment Offer Letter dated February 13, 2021 between Editas Medicine, Inc. (the “Company”), and you regarding the terms of your employment with the Company (the “Offer Letter”). This letter (the “Amendment”), shall be effective June 1, 2022, confirms the agreement between the Company and you regarding an amendment to the Offer Letter.
EDITAS MEDICINE, INC. INDUCEMENT RESTRICTED STOCK UNIT AGREEMENTInducement Restricted Stock Unit Agreement • February 26th, 2020 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
EDITAS MEDICINE, INC. NONSTATUTORY STOCK OPTION AGREEMENTNonstatutory Stock Option Agreement • February 28th, 2024 • Editas Medicine, Inc. • Biological products, (no disgnostic substances)
This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
EDITAS MEDICINE, INC. ADVISORY SERVICE AGREEMENTAdvisory Services Agreement • August 7th, 2020 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Advisory Services Agreement (the “Agreement”), is signed concurrently with the Separation Agreement dated May 1, 2020, to which this Agreement is attached as Exhibit A (the “Separation Agreement”) and effective as of May 4, 2020 (the “Effective Date”) is entered into by Editas Medicine, Inc., a Delaware corporation (the “Company”), and Judith R. Abrams, M.D., having an address set forth under his or her signature hereto (the “Advisor”).
OMNIBUS AMENDMENTCpf1 License Agreement, Cas9-Ii License Agreement • February 26th, 2021 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Omnibus Amendment (the “Amendment”) is entered into as of January 11, 2021 (the “Amendment Effective Date”), by and between The Broad Institute, Inc., a non-profit Massachusetts corporation, with a principal office at 415 Maine Street, Cambridge, MA 02142 (“Broad”) and Editas Medicine, Inc., a Delaware corporation, located at 11 Hurley Street, Cambridge, MA 02141 (“Editas”), and amends (i) that certain Cpf1 License Agreement, dated as of December 16, 2016 (the “Cpf1 Agreement”) and (ii) that certain Cas9-II License Agreement, dated as of December 16, 2016 (the “Cas9-II Agreement” and together with the Cpf1 Agreement, the “Agreements”). Broad and Editas may be referred to herein individually as a “Party” and collectively as the “Parties.”
VIA ELECTRONIC MAIL February 4, 2021 (revised) Cynthia Collins Dear Cindy:Severance Agreement • February 26th, 2021 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
As we discussed, your employment with Editas Medicine, Inc. (the “Company”) will end effective February 15, 2021 (the “Separation Date”). As we also discussed, you will be eligible to receive the severance benefits described in paragraph 1 below if you sign and return this letter agreement to me by February 26, 2021 (but no earlier than the Separation Date) and do not revoke your agreement (as described below). By signing and returning this letter agreement and not revoking your acceptance, you will be entering into a binding agreement with the Company and will be agreeing to the terms and conditions set forth in the numbered paragraphs below, including the release of claims set forth in paragraph 2. Therefore, you are advised to consult with an attorney before signing this letter agreement and you have been given at least twenty-one (21) days to do so. If you sign this letter agreement, you may change your mind and revoke your agreement during the seven (7) business day period after y
AMENDMENT NO. 1 TO AMENDED AND RESTATED CAS9‑I LICENSE AGREEMENTCas9-I License Agreement • March 7th, 2017 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Amendment No. 1 (the “Amendment”) to that certain Amended and Restated Cas9‑I License Agreement, by and among Editas Medicine, Inc. (the “Company”), President and Fellows of Harvard College (“Harvard”) and the Broad Institute, Inc. (“Broad”), dated December 16, 2016 (the “Agreement”), is made as of the 3rd day of March, 2017 (the “Amendment Effective Date”), by and among the Company, Harvard and Broad. Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same meanings as such terms are given in the Agreement.
EDITAS MEDICINE, INC. RESTRICTED STOCK UNIT AGREEMENTRestricted Stock Unit Agreement • January 22nd, 2019 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
